Proteopharma

ProteoPharma GmbH was a German biotechnology company focused on the development of innovative diagnostic and therapeutic approaches for neurodegenerative diseases, primarily Alzheimer's disease. The company's research centered on the detection and neutralization of toxic amyloid-beta oligomers, which are believed to be key drivers of cognitive decline. ProteoPharma developed a proprietary technology for the specific identification of these misfolded protein aggregates. Despite its early-stage research efforts and collaborations with academic institutions, the company ceased operations and was liquidated in the mid-2010s. Its work contributed to the broader understanding of protein misfolding in neurodegeneration.